Intra-Cellular Therapies (NASDAQ:ITCI) Releases Earnings Results, Beats Expectations By $0 15 EPS wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) had its target price upped by Mizuho from $82.00 to $96.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price objective points to a potential upside of 29.71% from the stock’s previous close. […]
Intra-Cellular Therapies (NASDAQ:ITCI) Earns Buy Rating from Needham & Company LLC themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average […]
Assenagon Asset Management S.A. grew its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 56.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 763,974 shares of the biopharmaceutical company’s stock after purchasing an additional 275,368 shares during the period. Assenagon Asset Management S.A.’s holdings in Intra-Cellular Therapies were worth $54,716,000 at […]